Search

Displaying results 1661 - 1670 of 10000 in total
  1. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.

    Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5ML
  2. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923] … [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas

  3. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [A274581] On December 19, 2025, the U.S. FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults.

  4. Drug

    Suzetrigine

    go.drugbank.com/drugs/DB18927
    ApprovedInvestigational

    [A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098] … Suzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain

  5. Drug

    Meningococcal polysaccharide vaccine group C

    go.drugbank.com/drugs/DB13890
    ApprovedInvestigational

    *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.

    Mixtures: Menjugate 10 Mikrogramm Injektionssuspension in einer Fertigspritze
  6. Drug

    Desipramine

    go.drugbank.com/drugs/DB01151
    Approved

    They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. … The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission.

    Synonyms: N-(3-methylaminopropyl)iminobibenzyl
  7. Drug

    Brompheniramine

    go.drugbank.com/drugs/DB00835
    Approved

    Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

    Synonyms: 3-(p-bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine, 3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamineMixtures: M-end Wc, M-end PE
  8. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. … [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery

  9. Drug

    Bismuth subsalicylate

    go.drugbank.com/drugs/DB01294
    ApprovedVet approved

    Bismuth subsalicylate is an antacid and anti-diarrheal agent. … [A230728] It is an active ingredient found in Pepto-Bismol, a common over-the-counter medication that is used to temporarily treat discomforts of the stomach and gastrointestinal tract.

  10. Drug

    Atidarsagene autotemcel

    go.drugbank.com/drugs/DB17538
    ApprovedInvestigational

    [L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic … [L45196] It was granted FDA approval under the brand name Lenmeldy in March 2024.[L50256]

    Synonyms: Autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene